²úÆ·ÏêÇé
| Ãû³Æ |
Human PD-L1 Protein |
| ËÞÖ÷ϸ°û |
HEK293 |
| ´¿¶È |
>95% by SDS-PAGE & HPLC |
| »ùÒòÃû |
CD274 |
| ÎïÖÖ |
Human |
| ±êÇ© |
His |
| »º³åÒº |
1¡ÁPBS£¬pH7.4 |
| ´¢´æ·½Ê½ |
For long term use, aliquot and store at -80¡ãC (avoiding multiple freeze-thaws). |
| SDS-PAGE |
|
| HPLC |
|
| ELISA |
|
Programmed death-ligand 1 (PD-L1, also known as CD274 or B7-H1) is a type I transmembrane protein and a key immune checkpoint molecule. It is widely expressed in various cell types, including tumor cells, antigen-presenting cells, and other immune-related tissues. PD-L1 interacts with its receptor PD-1 on T cells to inhibit T cell activation and proliferation, thereby promoting immune tolerance and preventing autoimmune responses. However, many tumors exploit this pathway to evade immune surveillance by upregulating PD-L1 expression. The PD-1/PD-L1 axis has become a central target in cancer immunotherapy, with multiple FDA-approved therapeutic antibodies blocking this interaction to restore anti-tumor immunity.
ÎïÁ÷ƽ̨£ºÄ¬ÈÏΪ¾©¶«ÎïÁ÷¡£ÈôÓÐÆäËûÐèÇó£¬ÇëÁªÏµ¶Ô½ÓÏúÊÛ¡£
·¢»õʱ¼ä£ºÈ·È϶©µ¥²¢Íê³É¸¶¿îºó1~2¸ö¹¤×÷ÈÕÄÚ°²ÅÅ·¢»õ¡£
·¢»õ·½Ê½£º±ù´ü»ò¸É±ù¡£